We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Jan 21, 2022
SHIVASHANKARA SWAMY M S
Jan 22, 2022
As patient is in visceral crisis and progressed while on endocrine therapy leaves less space for further endocrine therapy with CDK 4/6 inhibitors. Duration of adjuvant hormonal therapy and HR receptor status at progression are also helpful for further discussion. At this point of time I would suggest repeat biopsy and chemotherapy.
Jan 23, 2022
Jan 24, 2022
Cabazitaxel plus fulvestrant and CDK4/6 inhibitor
Jan 24, 2022
Jan 27, 2022
For aspiration of pleural fluid ? ongoing draining
? time between original Dx and metastatic disease ?
Could be for CDK4/6 with fulvestrant
May 28, 2022
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.